Company Description
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers.
Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy.
It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | John L. Flavin M.B.A., MBA, Ph.D. |
Contact Details
Address: 321 Harrison Avenue Boston, Massachusetts 02118 United States | |
| Phone | (617) 221-9059 |
| Website | pyxisoncology.com |
Stock Details
| Ticker Symbol | PYXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782223 |
| CUSIP Number | 747324101 |
| ISIN Number | US7473241013 |
| Employer ID | 83-1160910 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John L. Flavin M.B.A., MBA, Ph.D. | Co-Founder and Independent Chairman |
| Dr. Lara S. Sullivan M.D., MBA | Chief Executive Officer, President and Director |
| Pamela Yanchik Connealy M.B.A. | Chief Financial Officer and Chief Operating Officer |
| Ken Kobayashi FACP, M.D. | Chief Medical Officer |
| Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance and Corporate Controller |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | 424B2 | Prospectus |
| Apr 3, 2024 | EFFECT | Notice of Effectiveness |
| Apr 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 8-K | Current Report |